论文部分内容阅读
目的 研究人乳腺癌新鲜标本中ERβ蛋白检测的临床价值。 方法 用Westernblot法检测 86例乳腺癌手术标本中ERβ蛋白含量 ,分析它和临床病理生物学特性的关系。 结果 86例乳腺癌中 ,ERβ蛋白低表达 5 3例 ,占 61.6% ;高表达 3 3例 ,占 3 8.4%。表达水平和患者的绝经状态、病理分级、PR水平以及PS2水平相关 (P <0 .0 5 ) ;和肿瘤直径、腋淋巴结状态、ERα水平无关 (P >0 .0 5 )。根据ERα和PR分组后 ,ERα + /PR +组的ERβ蛋白高表达比例低于ERα -/PR -组 (P <0 .0 5 )。其余各亚组间ERβ蛋白表达差异无显著性 (P >0 .0 5 )。结论 ERβ蛋白表达可能是提示乳腺癌患者预后和内分泌治疗耐药有价值的指标
Objective To study the clinical value of ERβprotein detection in fresh human breast cancer specimens. Methods Western blotting was used to detect the ERβ protein in 86 cases of breast cancer. The relationship between ERβ protein and clinicopathological features was analyzed. Results 86 cases of breast cancer, ERβ protein low expression of 53 cases, accounting for 61.6%; high expression of 33 cases, accounting for 3 8.4%. The expression level correlated with the menopausal status, pathological grade, PR level and PS2 level (P <0.05), but not with tumor diameter, axillary lymph node status and ERα level (P> 0.05). According to the ERα and PR groups, the ERβprotein expression ratio in ERα + / PR + group was lower than that in ERα - / PR - group (P <0.05). There was no significant difference in ERβprotein expression between other subgroups (P> 0.05). Conclusion The expression of ERβ protein may be a valuable indicator of prognosis and endocrine drug resistance in patients with breast cancer